These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 37173281)

  • 21. Restricted Mean Survival Time Analysis to Estimate SGLT2i-Associated Heterogeneous Treatment Effects on Primary and Secondary Prevention of Cardiorenal Outcomes in Patients With Type 2 Diabetes in Taiwan.
    Peng ZY; Yang CT; Kuo S; Wu CH; Lin WH; Ou HT
    JAMA Netw Open; 2022 Dec; 5(12):e2246928. PubMed ID: 36520437
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study.
    Jeong HE; Park S; Noh Y; Bea S; Filion KB; Yu OHY; Jang SH; Cho YM; Yon DK; Shin JY
    BMC Med; 2023 Feb; 21(1):47. PubMed ID: 36765407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
    Ling AW; Chan CC; Chen SW; Kao YW; Huang CY; Chan YH; Chu PH
    Cardiovasc Diabetol; 2020 Nov; 19(1):188. PubMed ID: 33158436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between sodium-glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation.
    Fichadiya A; Quinn A; Au F; Campbell D; Lau D; Ronksley P; Beall R; Campbell DJT; Wilton SB; Chew DS
    Europace; 2024 Mar; 26(3):. PubMed ID: 38484180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contemporary use of SGLT2 inhibitors in heart failure patients with diabetes mellitus: a comparison of DPP4 inhibitors in a nationwide electric health database of the superaged society.
    Nakai M; Iwanaga Y; Kanaoka K; Sumita Y; Nishioka Y; Myojin T; Kubo S; Okada K; Soeda T; Noda T; Sakata Y; Imamura T; Saito Y; Yasuda S; Miyamoto Y
    Cardiovasc Diabetol; 2022 Aug; 21(1):157. PubMed ID: 35964039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of morbidity and mortality in patients with type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor and/or dipeptidyl peptidase-4 inhibitor: a nationwide study.
    Sütő G; Molnár GA; Rokszin G; Fábián I; Kiss Z; Szekanecz Z; Poór G; Jermendy G; Kempler P; Wittmann I
    BMJ Open Diabetes Res Care; 2021 Jan; 9(1):. PubMed ID: 33472796
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of sodium-glucose cotransporter 2 inhibitors for renal prognosis and mortality in diabetes patients with heart failure on diuretics.
    Weng YF; Chen CY; Hwang SJ; Huang YB
    Kaohsiung J Med Sci; 2023 Apr; 39(4):416-425. PubMed ID: 36625282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucose-Lowering Agents and the Risk of Hypoglycemia: a Real-world Study.
    Lyu B; Hwang YJ; Selvin E; Jameson BC; Chang AR; Grams ME; Shin JI
    J Gen Intern Med; 2023 Jan; 38(1):107-114. PubMed ID: 35831767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis.
    Mui JV; Zhou J; Lee S; Leung KSK; Lee TTL; Chou OHI; Tsang SL; Wai AKC; Liu T; Wong WT; Chang C; Tse G; Zhang Q
    Front Cardiovasc Med; 2021; 8():747620. PubMed ID: 34746262
    [No Abstract]   [Full Text] [Related]  

  • 30. Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors in Japan: A real-world administrative database analysis.
    Kashiwagi A; Shoji S; Kosakai Y; Yoshinaga Y; Rokuda M
    J Diabetes Investig; 2024 Mar; 15(3):374-387. PubMed ID: 38112598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of sodium-glucose co-transporter-2 inhibitors on dementia and cardiovascular events in diabetic patients with atrial fibrillation.
    Chen YY; Chang HC; Lin YJ; Chien KL; Hsieh YC; Chung FP; Lin CH; Lip GYH; Chen SA
    Diabetes Metab Res Rev; 2024 Feb; 40(2):e3775. PubMed ID: 38340046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of cardiovascular and renal outcomes between dapagliflozin and empagliflozin in patients with type 2 diabetes without prior cardiovascular or renal disease.
    Lim J; Hwang IC; Choi HM; Yoon YE; Cho GY
    PLoS One; 2022; 17(10):e0269414. PubMed ID: 36251654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The epidemiology of ketosis and low bicarbonate concentration in inpatients treated with sodium-glucose linked cotransporter inhibitors or dipeptidyl peptidase-4 inhibitors.
    Huang W; Whitelaw J; Kishore K; Neto AS; Holmes NE; Marhoon N; Bellomo R; Ekinci EI
    J Diabetes Complications; 2023 Aug; 37(8):108522. PubMed ID: 37311358
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sodium-Glucose Cotransporter 2 Inhibitors vs Incretin-Based Drugs and Risk of Fractures for Type 2 Diabetes.
    Ko HY; Bea S; Jeong HE; Park S; Cho YM; Kong SH; Shin JY
    JAMA Netw Open; 2023 Sep; 6(9):e2335797. PubMed ID: 37751205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cardiovascular and Renal Outcomes With Sodium-Glucose Cotransporter-2 Inhibitors and Dipeptidyl Peptidase-4 Inhibitors Combination Therapy: A Meta-Analysis of Randomized Cardiovascular Outcome Trials.
    Singh AK; Singh A; Singh R
    Endocr Pract; 2023 Jul; 29(7):509-516. PubMed ID: 37037286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fracture risks associated with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients across eGFR and albuminuria categories: A population-based study in Hong Kong.
    Lui DTW; Wu T; Tang EHM; Au ICH; Lee CH; Woo YC; Tan KCB; Wong CKH
    Diabetes Res Clin Pract; 2023 Mar; 197():110576. PubMed ID: 36780955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of patients with type 2 diabetes treated with SGLT-2 inhibitors versus DPP-4 inhibitors. An Italian real-world study in the context of other observational studies.
    Longato E; Bonora BM; Di Camillo B; Sparacino G; Tramontan L; Avogaro A; Fadini GP
    Diabetes Res Clin Pract; 2021 Sep; 179():109024. PubMed ID: 34454002
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lower Risks of New-Onset Hepatocellular Carcinoma in Patients With Type 2 Diabetes Mellitus Treated With SGLT2 Inhibitors Versus DPP4 Inhibitors.
    Chou OHI; Ning J; Chan RNC; Chung CT; Huang H; Ng K; Dee EC; Lee S; Kaewdech A; Chow AKM; Man NK; Liu T; Jing F; Cheung BMY; Tse G; Zhou J
    J Natl Compr Canc Netw; 2024 Jun; 22(2D):. PubMed ID: 38862004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
    Udell JA; Yuan Z; Rush T; Sicignano NM; Galitz M; Rosenthal N
    Circulation; 2018 Apr; 137(14):1450-1459. PubMed ID: 29133607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sodium-glucose co-transporter-2 inhibitors and the risk of urosepsis: A multi-site, prevalent new-user cohort study.
    Fisher A; Fralick M; Filion KB; Dell'Aniello S; Douros A; Tremblay É; Shah BR; Ronksley PE; Alessi-Severini S; Hu N; Bugden SC; Ernst P; Lix LM;
    Diabetes Obes Metab; 2020 Sep; 22(9):1648-1658. PubMed ID: 32383792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.